High Quality Antibodies

Vertebrate Antibodies Limited (VAL) is a biotech spinout company from the University of Aberdeen with a focus on the development of antibodies to targets within a wide range of organisms for research and clinical applications. VAL supports the life sciences community by providing and developing a large range of high quality antibodies.

VAL’s antibodies will be developed for high performance within a range of downstream applications including: Western Blotting, Immunohistochemistry, Immunofluorescence, ELISA and Flow Cytometry. Antibodies will be designed to specifically target key cellular components relevant to cancer, immunological disorders, neurobiology and disease across different species.

Announcements:

  • April 2015 April 2015 – Development of monoclonal antibodies for parasite-specific molecules In April 2015 a European Union Horizon 2020 Project funded to support the prospective fish-farming industry has started. ParaFishControl (www.parafishcontrol.eu) overarching goal is to increase the sustainability and competitiveness of the European aquaculture industry by improving our understanding of fish-parasite interactions and by developing innovative ...
  • October 2014 VAL new antibodies towards key zebrafish targets: The antibodies are specific to zebrafish targets involved in key biological pathways including immunity, angiogenesis, tumour suppressors and drug metabolisers. The list are as follows; CD4, FOXP3, IFNγ(1), p53, MMP9, AKT1, FLT1, FGF1, TIMP2a, PXR and CYP3C1. Datasheets available on the zebrafish page. Kick Start Award                                                                                                               (in progress) In collaboration with ...
  • June 2014 VAL new antibodies towards key immune targets in salmonids: In recent years, aquaculture has expanded significantly and become a major economic sector. In the last two decades, commercial vaccines have become available through research to prevent infectious diseases caused by some pathogens. However there is still a long way to go to develop effective vaccines against ...
  • April 2014 CRT exclusive agreement: Vertebrate Antibodies Ltd reached an agreement with Cancer Research Technology (CRT) to exclusively license a number of their monoclonal antibodies for Research Only.  The antibodies are specific towards the following human targets; BCLAF1, CCT2, CYP1A2, CYP1A, CYP2A6, CYP2E1, CYP2R1, CYP4F11, CYP4A11, CYP4V2, CYP4Z1, CYP3A4, CYP3A5, CYP3A7, CYP7B1, CYP8B1, CYP26A1, CYP26B1, CYP26C1, CYP39A1, CYP51A1, ...
  • January 2014 SMART-SCOTLAND feasibility study award “Discovery of colorectal cancer biomarkers and validation of antibodies towards them for use as diagnostic or therapeutic agents”.  Over the duration of 18 months and in collaboration with Professor Graeme Murray at Aberdeen University, the projects aims to deliver a portfolio of novel tumour biomarkers combined with clinical probes for diagnostic, ...
  • January 2012 Knowledge Transfer and Exchange Award in collaboration with Dr Jun Zou at the Scottish Fish Immunology Research Centre (SFIRC). The award aimed at developing assays to monitor vaccine performance in salmonids. Outcome:  monoclonal antibodies are developed to key cytokines i.e. INFg. Quantitative and qualitative assays are being optimised by scientists at SFIRC (more update to follow).   Kick ...
  • July 2012 Kick Start award in collaboration with Professor Graeme Murray, University of Aberdeen, with focus on the discovery of colorectal cancer biomarkers and the validation of antibodies towards them for use as prognostic agents. Outcome: The project targeted retinoic acid metabolising enzymes. Retinoic acid is a metabolite of vitamin A and is essential for normal cell growth. Monoclonal ...